AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Aquestive Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$3.83+0.05 (+1.32%)

Close on Oct 19, 2026

Market cap: $478.73M
P/E (TTM): –
Dividend yield: –

Aquestive Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Depreciation & Amortization	0.55	0.72	1.35	2.39	2.96	3.44	2.91	3.24	3.75
Stock-Based Compensation	7.62	7.10	2.69	4.38	6.82	6.58	7.07	30	0
Deferred Income Taxes	0	0	0	0	–	–	–	–	–
Other Non-Cash Items	0.00	-0.10	0.20	0.05	0.30	-0.19	-0.36	–	–
Change in Accounts Receivable	-10	1.09	-3.07	7.35	-5.35	6.18	-6.82	-0.41	4.69
Change in Inventory	-0.13	0.73	-0.99	-1.74	-1.58	0.40	2.58	-1.43	-1.13
Change in Accounts Payable	20	2.78	-1.02	1.63	1.23	-5.19	-7.87	11	2.94
Change in Unearned Revenue	-0.57	-13	0.97	25	3.56	-0.83	1.60	-0.63	0.55
Operating Cash Flow	-52	-36	-6.38	-9.82	-33	-45	-60	-13	5.82
Capital Expenditures	-0.56	-0.16	-1.00	-1.02	-0.91	-0.52	-0.66	-1.82	-2.07
Investing Cash Flow	-0.56	-0.16	-1.00	-2.52	-0.91	-0.52	-0.66	-1.82	-2.07
Debt Issued	–	0	31	0	–	0	70	0	5.00
Debt Repaid	-0.03	-0.02	-52	0	0	-23	-50	0	–
Taxes Paid on Share-Based Awards	-0.81	-1.10	-0.01	0.00	-0.01	-0.10	-2.83	-6.03	0
Financing Cash Flow	103	84	3.97	12	30	28	50	58	4.41
Net Change in Cash	50	48	-3.40	-0.75	-3.78	-18	–	43	8.17
Free Cash Flow	-53	-36	-7.38	-11	-34	-46	-61	-15	3.76
Income Taxes Paid	0	0.31	0	–	–	–	–	–	–
Interest Paid	6.10	7.10	4.60	6.44	6.44	8.49	7.34	6.05	5.81

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 67.0%
Operating margin: -97.5%
Net margin: -144.6%
Return on equity, FY2025: 178.6%

Financial strength

Current ratio: 7.19
Debt to equity: -0.90
Debt to assets: 38.4%
Cash to current liabilities: 597.7%

Valuation

P/E ratio: –
Price to sales: 8.85
Price to book: –
Dividend yield: –